210 related articles for article (PubMed ID: 15820490)
21. The V-twin system (Dade Behring Laboratories): a useful tool for immunosuppressive drug monitoring.
Elaerts S; Olejnik Y; Bonardet A; Garrigue V; Mourad G; Cristol JP; Dupuy AM
Transplant Proc; 2005; 37(1):167-71. PubMed ID: 15808583
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods.
Hamwi A; Salomon A; Steinbrugger R; Fritzer-Szekeres M; Jäger W; Szekeres T
Am J Clin Pathol; 2000 Oct; 114(4):536-43. PubMed ID: 11026099
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
[TBL] [Abstract][Full Text] [Related]
24. Comparison of three methods for cyclosporine therapeutic monitoring.
Jebabli N; Klouz A; Bahlous A; Gaïes E; Trabelsi S; Lakhal M; Belkahia C
Transplant Proc; 2007 Oct; 39(8):2557-9. PubMed ID: 17954172
[TBL] [Abstract][Full Text] [Related]
25. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
[TBL] [Abstract][Full Text] [Related]
26. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients.
Westley IS; Taylor PJ; Salm P; Morris RG
Ther Drug Monit; 2007 Oct; 29(5):584-91. PubMed ID: 17898648
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan.
Chou NK; Chen RJ; Ko WJ; Lin HL; Yu SY; Chen YS; Hsu RB; Lee CM; Lin FY; Wang SS
Transplant Proc; 2004 Oct; 36(8):2393-5. PubMed ID: 15561260
[TBL] [Abstract][Full Text] [Related]
28. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine therapeutic monitoring with Cmax in kidney transplant recipients: does it fit for all populations?
El-Agroudy AE; Ismail AM; Nassar M; Ghoneim MA
Exp Clin Transplant; 2008 Dec; 6(4):282-6. PubMed ID: 19338490
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.
Cattaneo D; Merlini S; Baldelli S; Bartolini B; Nicastri A; Gotti E; Remuzzi G; Perico N
Ther Drug Monit; 2006 Oct; 28(5):643-9. PubMed ID: 17038879
[TBL] [Abstract][Full Text] [Related]
31. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
32. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
Li J; Dahmen U; Beckebaum S; Cicinnati V; Valentin-Gamazo C; Frilling A; Malago M; Broelsch CE
Eur J Med Res; 2006 Apr; 11(4):139-45. PubMed ID: 16720277
[TBL] [Abstract][Full Text] [Related]
33. Analytical performance of the CEDIA cyclosporine PLUS whole blood immunoassay.
Butch AW; Fukuchi AM
J Anal Toxicol; 2004 Apr; 28(3):204-10. PubMed ID: 15107152
[TBL] [Abstract][Full Text] [Related]
34. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
[TBL] [Abstract][Full Text] [Related]
35. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
[TBL] [Abstract][Full Text] [Related]
36. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
Videla C; Vega J; Borja H
Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ
Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cyclosporine concentrations in renal transplant recipients using ACMIA and mFPIA methods.
Kagawa Y; Yanagawa M; Muraki Y; Iwamoto T; Mizutani H; Sugimura Y; Kojima M
Clin Biochem; 2004 Nov; 37(11):1016-21. PubMed ID: 15498531
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
